About

Carmen Di Marino joined Dompé as chief legal officer in 2013, in order to support and advise on the group’s expansion strategy in international markets. She is currently in charge of managing and coordinating the legal affairs department at a global level, which consists of legal and intellectual property divisions with a team of seven people composed of one patent attorney, four lawyers and two paralegals. Di Marino is also a member of Dompé’s executive team reporting to the president and CEO of the group, showing her business nous and the trust in which the business places in her counsel. From 2015 to 2017 she also managed and coordinated the company’s compliance division. Her approach to leadership is to navigate and orient business decisions through complex and uncertain conditions with prospective thinking, identify and mitigate risks beforehand and motivate and support people growing by acting as mentor for others. In her time at Dompé she has contributed to the international expansion of the company group through the incorporation of new legal entities in the US, England, France, Germany, Spain, Albania, Kosovo and Japan. She also created the first global compliance division and implemented an automatic system for the generation of contracts by business people through a questionnaire that, according to the answers provided by the user, identifies the terms, conditions and provisions to be included in the contract templates. In addition, she has been in the forefront of Dompé’s expansion. She was involved with the acquisition in 2016 of the pharmaceutical division from Bracco dedicated to the distribution, marketing and sale of pharmaceutical products, medical devices, medical and surgical tools, food supplements, food and cosmetics in Italy, the Vatican City State and San Marino. As a result of this transaction, Dompé has taken over the assets, contracts and rights of Bracco in relation to the products acquired. She was also involved in the in-licensing in 2017 of Zalmoxis from Molmed, a gene therapy for the treatment of acute leukemia. The license rights acquired are related to the European territory with an option to extend the licence in Australia and Canada. This has been the first transaction regarding a gene therapy for the Italian market, evincing Di Marino’s ability to advise on cutting-edge matters in the sector. Finally, she orchestrated the legal matters relating to the out-licensing to Omega Pharma/Perrigo of the commercialisation of Okitask products in around 50 countries in the world and definition of a co-branding marketing strategy for those products. When discussing where her career has taken her, she explains she has ‘achieved very good results in my in-house career thanks to my previous work experience at Paul Hastings. In fact, during my private practice [career] in such law firms I was able to spend almost a year in New York, I worked in complex and sophisticated matter